6.3.5.6. adjuvant treatment pn1 disease. 6.3.5.6.1. adjuvant androgen ablation alone combination rp early adjuvant ht pn+ pca shown achieve 10-year css rate 80% shown significantly improve css os prospective rcts . however, trials included mostly patients high-volume nodal disease multiple adverse tumour characteristics findings may apply men less extensive nodal metastases. 6.3.5.6.2. adjuvant radiotherapy combined adt pn1 disease retrospective multi-centre cohort study, maximal local control rt prostatic fossa appeared beneficial pca patients pn1 rp, treated ‘adjuvantly‘ continuous adt (within six months surgery irrespective psa). beneficial impact adjuvant rt survival patients pn1 pca highly influenced tumour characteristics. men low-volume nodal disease (< 3 lns), isup grade group 2–5 pt3–4 r1, well men 3 4 positive nodes likely benefit rt surgery, subgroups . contrast, retrospective multi-centre study including 1,614 patients median follow-up 7,02 years assessed art + adt. adjuvant rt compared srt associated decreased all-cause mortality reduction increased additional positive pelvic ln, first one highest effect 3 positive nodes . data agreement us national cancer database analysis based 5,498 patients . another us national cancer database study including 8,074 pn1 patients reports improved os adt plus ebrt (including pelvic lns) vs. observation vs. adt alone men single multiple adverse pathological features. men without adverse pathological features benefit immediate adjuvant therapy . sr literature, rt without adt associated improved survival men locally-advanced disease higher number positive nodes . radiotherapy pelvic lymphatics prostate fossa plus long-term adt offered patients pn1 disease. . however, optimal duration adt still unkown. 6.3.5.6.3. observation pn1 patients radical prostatectomy extended lymph node dissection several retrospective studies sr addressed management patients pn1 pca rp . subset patients limited nodal disease (1–2 positive lns) showed favourable oncological outcomes require additional treatment. analysis 209 pn1 patients one two positive lns rp showed 37% remained metastasis-free without need salvage treatment median follow-up 60.2 months . touijer et al., reported results 369 pn1-positive patients (40 329 without adjuvant treatment) showed higher pathologic grade group > 3 positive lns significantly associated increased risk bcr multivariable analysis . biochemical-free survival rates pn1 patients without adjuvant treatment ranged 43% four years 28% ten years . reported css rates 78% five years 72% ten years. majority patients managed initial observation surgery, favourable disease characteristics, 63% one positive node . initial observation followed early salvage treatment time recurrence may represent safe option selected patients low disease burden .